Search - tctmd.com

Displaying 161 - 180 of 375

Sort: Relevancy | Date

Presentation EAS 2018

LPA variants, risk of coronary disease, and estimated clinical benefit of lipoprotein(a) lowering therapies: a Mendelian randomization analysis

Presenter: Brian A. Ference

May 07, 2018

Presentation CIT 2018

Optimal Pharmacology and PCI Strategy in STEMI & Multivessel Disease

Presenter: Ran Kornowski

March 23, 2018

Presentation ACC 2018

CANTOS: Anti-Inflammatory Therapy with Canakinumab for the Prevention and Management of Diabetes

Presenter: Brendan M. Everett

March 12, 2018

Presentation ACC 2018

The PHARMCLO Study: A Prospective, Randomised, Multicentre Study of a Pharmacogenomic Approach to the Selection of Antiplatelet Therapy in Acute Coronary Syndromes

Presenter: Diego Ardissino

March 12, 2018

Comparison of Effectiveness, Safety, and The Net Clinical Outcome Between Different Direct Oral Anticouagulants

Presentation ACC 2018

Comparison of Effectiveness, Safety, and The Net Clinical Outcome Between Different Direct Oral Anticoagulants

Presenter: Steve Deitelzweig

March 12, 2018

Presentation ACC 2018

Results of the SWAP (Switching Antiplatelet Therapy) - 4 Study

Presenter: Francesco Franchi

March 11, 2018

Presentation ACC 2018

Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout and Cardiovascular Disease (The CARES Trial)

Presenter: William B. White

March 11, 2018

Presentation ACC 2018

The ODYSSEY OUTCOMES Trial: Topline Results Alirocumab in Patients After Acute Coronary Syndrome

Presenter: Philippe Gabriel Steg

March 10, 2018

Presentation JIM 2018

Case: Immediately after PCI and BAV the patient was given aspirin 250 mg iv and Plavix 300 mg

Presenter: Ferdinando Varbella

February 23, 2018

Presentation JIM 2018

Vascular Complications

Presenter: Bernhard Reimers

February 23, 2018

Presentation JIM 2018

Case: Immediate PCI + downstream clopidogrel

Presenter: Giuseppe Tarantini

February 23, 2018

Presentation JIM 2018

Clinical Case: Management of Long-Term DAPT

Presenter: Ugo Limbruno

February 23, 2018

Presentation

Chronic Ischaemic Cardiovascular Disease (CICD) ESC Pilot Registry: 6-Month Follow-Up

January 19, 2018

Presentation TTT 2018

Prolonged DAPT should be Standard of Care Post PCI?

Presenter: Tan Huay Cheem

January 14, 2018

Presentation Controversies and Advances 2017

Does IMPROVE-IT and FOURIER. Confirm or Refute the LDL Hypothesis?

Presenter: Sanjay Kaul

November 16, 2017

Presentation AHA 2017

Insights from the FOURIER Trial

Presenter: Marc P. Bonaca

November 15, 2017

Presentation AHA 2017

Effects of Anacetrapib on the Incidence of New-Onset Diabetes Mellitus and on Vascular Events in People With Diabetes

Presenter: Louise Bowman

November 14, 2017

Presentation TCT 2017

Adjunctive Pharmacotherapy During and After TAVR: Current Trends, New Studies, and the Case for Short-term (3-6 months) Systemic Anticoagulation

Presenter: Eberhard Grube, James B. Hermiller Jr., Pascal Vranckx

November 01, 2017

Presentation TCT 2017

Managing AS Patients With Atrial Fibrillation in TAVR Patients Pharmacotherapy Considerations and LAAC Possibilities (WATCH-TAVR Trial)

Presenter: Samir R. Kapadia

November 01, 2017

Presentation TCT 2017

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation - How to Incorporate the Results in Clinical Practice

Presenter: Deepak L. Bhatt, C. Michael Gibson

November 01, 2017

Advertisement

LPA variants, risk of coronary disease, and estimated clinical benefit of lipoprotein(a) lowering therapies: a Mendelian randomization analysis

Optimal Pharmacology and PCI Strategy in STEMI & Multivessel Disease

CANTOS: Anti-Inflammatory Therapy with Canakinumab for the Prevention and Management of Diabetes

The PHARMCLO Study: A Prospective, Randomised, Multicentre Study of a Pharmacogenomic Approach to the Selection of Antiplatelet Therapy in Acute Coronary Syndromes

Comparison of Effectiveness, Safety, and The Net Clinical Outcome Between Different Direct Oral Anticoagulants

Results of the SWAP (Switching Antiplatelet Therapy) - 4 Study

Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout and Cardiovascular Disease (The CARES Trial)

The ODYSSEY OUTCOMES Trial: Topline Results Alirocumab in Patients After Acute Coronary Syndrome

Case: Immediately after PCI and BAV the patient was given aspirin 250 mg iv and Plavix 300 mg

Vascular Complications

Case: Immediate PCI + downstream clopidogrel

Clinical Case: Management of Long-Term DAPT

Chronic Ischaemic Cardiovascular Disease (CICD) ESC Pilot Registry: 6-Month Follow-Up

Prolonged DAPT should be Standard of Care Post PCI?

Does IMPROVE-IT and FOURIER. Confirm or Refute the LDL Hypothesis?

Insights from the FOURIER Trial

Effects of Anacetrapib on the Incidence of New-Onset Diabetes Mellitus and on Vascular Events in People With Diabetes

Adjunctive Pharmacotherapy During and After TAVR: Current Trends, New Studies, and the Case for Short-term (3-6 months) Systemic Anticoagulation

Managing AS Patients With Atrial Fibrillation in TAVR Patients Pharmacotherapy Considerations and LAAC Possibilities (WATCH-TAVR Trial)

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation - How to Incorporate the Results in Clinical Practice

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content